BCM
BMRN icon

Boone Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Boone Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.9M Buy
547,871
+135,991
+33% +$7.93M 9.48% 6
2025
Q4 		$24.5M Buy
411,880
+83,334
+25% +$4.54M 7.68% 5
2025
Q3 		$17.8M Sell
328,546
-118,903
-27% -$6.8M 5.83% 9
2025
Q2 		$24.6M Buy
447,449
+120,170
+37% +$7.08M 10.55% 3
2025
Q1 		$23.1M Buy
+327,279
New +$22M 7.87% 6

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boone Capital Management's BMRN Position: Q1 2026 in Review

Boone Capital Management increased its BioMarin Pharmaceuticals (BMRN) stake by 33% in Q1 2026, buying an estimated $7.93M and bringing the position to 547,871 shares worth $30.9M. The position accounts for 9.48% of the portfolio, ranked #6.

Boone Capital Management first reported a position in BMRN in Q1 2025 and has held it in 5 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Boone Capital Management held 547,871 shares of BioMarin Pharmaceuticals worth $30.9M as of Q1 2026.
  • Boone Capital Management bought 135,991 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $7.93M.
  • BioMarin Pharmaceuticals made up 9.48% of Boone Capital Management's portfolio in Q1 2026, its #6 holding.
  • Boone Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Boone Capital Management's 13F filing for Q1 2026, filed 15 May 2026.